π¨BREAKING: IDSA, along with AAP, APHA, ACP and others, has filed a lawsuit against HHS/Secretary Kennedy to stop unlawful changes to vaccine policy and defend public health.
We refuse to stand by while Americaβs public health safeguards are torn apart. bit.ly/4lm7UkW
07.07.2025 17:19 β
π 180
π 100
π¬ 7
π 9
@astct.bsky.social has #ID #HSCT #CAR-T guidelines in TCT Journal
transplantid.net "GUIDELINES"βΆοΈ "ASTCT Guidelines"π
#οΈβ£ π : Management of parainfluenza and hMPV after HSCT and CAR-T
Thanks Aneela Majeed @clevelandclinic.bsky.social!
transplantid.net/5WJIIMGH
03.07.2025 16:15 β
π 0
π 1
π¬ 0
π 0
Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis
Isavuconazole (ISA) is a newer triazole that has activity against most mold species and has been utilized for prophylaxis as well as treatment in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT). However, several studies have documented breakthrough invasive fungal infections (bIFIs). Thus, we conducted a systematic review and meta-analysis to investigate the incidence of bIFIs among patients receiving ISA prophylaxis.MethodsWe conducted a systematic review and meta-analysis of the published literature using the concept of ISA, HSCT, and HM from 5 search engines. In patients with HSCT and HM, the pooled incidence of bIFI while undergoing ISA prophylaxis was calculated via the DerSimonian-Laird random effect model.ResultsThe systematic review and meta-analysis included 35 and 19 studies, respectively. In total, 991 patients were identified as using ISA prophylaxis, and the majority had either acute myeloid leukemia or myelodysplastic syndrome (69.9%). The pooled incidence of proven/probable bIFI was 7% (95% CI, 4%β12%, I2 = 55%). The most common pathogen was Aspergillus species (43.1%), followed by Candida (22.4%) and Mucorales (12.1%). In 19 studies, mortality rates were documented and ranged between 0% and 100%; the majority of which were >50%.ConclusionsIn patients with HM or HSCT, we found a high incidence of bIFI while undergoing ISA prophylaxis, with high mortality. Given the lack of randomized clinical trials evaluating ISA in this indication, its role in prophylaxis remains unclear.
π§ͺ ISA prophylaxis in 991 patients (69.9% with AML/MDS) showed 7% bIFI incidence (95% CI, 4%-12%). Common pathogens: Aspergillus (43.1%), Candida (22.4%). Mortality >50% in most studies.
#idsky
19.04.2025 04:00 β
π 2
π 1
π¬ 0
π 1
#IDOnc
19.04.2025 22:53 β
π 0
π 0
π¬ 0
π 0
Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial
Vaccine immunogenicity is reduced in kidney transplant recipients (KTRs), especially in those using mycophenolate mofetil (MMF). Whether replacement of MMF by everolimus improves vaccine immunogenicity is unknown.MethodsKTRs were randomized 1:1 to continue MMF or switch to everolimus. Participants received one coronavirus disease 2019 (COVID-19) booster vaccination and two herpes zoster (HZ) vaccinations at 6, 10 and 14 weeks postrandomization. Primary outcome was the neutralizing antibody response 28 days after COVID-19 vaccination. Secondary outcomes included antibody and T-cell responses 28 days after COVID-19 and HZ vaccination, and safety.ResultsIn 110 KTRs, COVID-19 vaccination resulted in comparable Omicron XBB.1.5 neutralizing antibody titers in the everolimus versus MMF group (308 [74.4β1314] vs 327 [115β897]; P = .83), whereas severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Spike-specific T-cell responses were slightly lower with everolimus (118 [32.1β243] vs 228 [113β381] spot-forming cells [SFCs]/106 peripheral blood mononuclear cells [PBMCs]; P = .02). HZ vaccination led to higher varicella zoster virus (VZV) glycoprotein E (gE)βspecific immunoglobulin G titers with everolimus (2192 [888β4523] vs 1101 [440β2078] 50% endpoint titer; P = .004), while VZV gE-specific T-cell responses were similar (85.0 [27.5β155] vs 115 [50.0β258] SFCs/106 PBMCs; P = .24). Besides known side effects, everolimus led to more bacterial infections (27.3% vs 11.1%; P = .03).ConclusionsSix weeksβ replacement of MMF by everolimus in KTRs does not improve COVID-19 booster vaccine immunogenicity, whereas 10 weeksβ replacement enhances humoral HZ vaccine immunogenicity. While replacing MMF by everolimus may improve vaccine responses, its timing and potential risks require careful consideration.
In 110 KTRs, everolimus vs MMF showed similar COVID-19 antibody titers (308 vs 327; P=.83) but lower T-cell responses (118 vs 228; P=.02). HZ vaccine titers improved with everolimus (2192 vs 1101; P=.004). More infections with everolimus (27.3% vs 11.1%; P=.03).
#idsky
15.04.2025 22:30 β
π 2
π 1
π¬ 1
π 0
What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients
Patients with overt immunosuppression are at risk of cytomegalovirus infection, which can lead to, or develop during, ICU admission. Learn more about its broad clinical presentations, risk factorsβ¦
Patients with overt immunosuppression are at risk of cytomegalovirus infection, which can lead to, or develop during, #ICU admission.
Learn more about its broad clinical presentations, risk factors and management strategies, with this #EdsChoice review.
π buff.ly/GQHzurR
#IDSky #MedSky #CMV
13.04.2025 13:15 β
π 1
π 1
π¬ 0
π 0
#IDOnc
06.04.2025 00:06 β
π 1
π 0
π¬ 0
π 0
Distribution and prevalence of fungemia: a five-year retrospective multicentric survey in Venetian region, Italy
Invasive fungal infections, significantly impact hospitalized and immunocompromised populations. Recent trends showed a shift from Candida albicans to non-albicans Candida (NAC) species, raising concerns about antifungal resistance.ObjectivesOur study focuses on the distribution of fungal species in blood cultures obtained from different healthcare settings, including hospitals, long-term care facilities, and community health centers in the Venetian region of Italy.MethodsWe retrospectively analyzed all consecutive blood culture isolates across 5 hospitals, 38 long-term care facilities, and 24 sample collection centers (blood exams and culture) from 2019 to 2023.ResultsBetween 2019 and 2023, 11,552 microorganisms were isolated from blood cultures; 693 (6.0%) were fungi. The yearly prevalence ranged from 5.2% in 2019 to 6.1% in 2023. C. albicans isolates decreased significantly, from 60.0% in 2019 to 43.1% in 2023. NAC species showed significant growth, particularly C. parapsilosis sensu stricto (from 23.6% in 2019 to 28.8% in 2023), C. tropicalis (from 0.0% in 2019 to 7.2% in 2023), and N. glabratus (from 9.1% in 2019 to 11.8% in 2023). Medical wards consistently recorded the highest number of cases (429/693, 61.9%), with C. albicans predominating in earlier years. Resistance to amphotericin B rose sharply in C. parapsilosis ss. (22.5% in 2022), while fluconazole resistance in N. glabratus remained high (peaking at 85.7% in 2021).ConclusionThe increasing dominance of NAC species and rising resistance trends underscore the necessity for enhanced diagnostics, infection prevention, and antifungal stewardship. Future research should incorporate clinical data to optimize fungemia management strategies.
π¦ From 2019-2023, 11,552 blood cultures showed 693 (6.0%) fungi. C. albicans dropped from 60% to 43.1%, while NAC species grew, e.g., C. parapsilosis from 23.6% to 28.8%. Resistance to amphotericin B rose to 22.5%.
#idsky
26.03.2025 01:00 β
π 5
π 1
π¬ 0
π 0
#IDOnc
25.03.2025 02:59 β
π 0
π 0
π¬ 0
π 0
Cytomegalovirus (CMV) infection in immunocompromised ICU patients can lead to severe complications like pneumonia and encephalitis. Distinguishing between reactivation and active disease is essential for targeted treatment and improving outcomes. zurl.co/dCQvA
14.03.2025 13:00 β
π 3
π 1
π¬ 0
π 0
Stenotrophomonas maltophilia - the cockroach of the ICU. After broad-spectrum abx nuke a patientβs microbiome, itβs often the last one standingβesp. in vented patients. (VAP in a patient on mero, think Steno)
For years, TMP-SMX was the go-to, but alternatives are needed.
π§΅(1/6)
13.03.2025 18:04 β
π 4
π 3
π¬ 2
π 0
AUC0-24/MIC for two different durations of antifungal treatment in ICU: 1-3 days vs 4-7 days, shown for various antifungals (and for caspofungin and anidulafungin shown separately for C albicans and C glabrata)
PK/PD target-related exposures per occasion of the study antifungals prescribed for treatment. The shaded area represents the PK/PD target used in this study. For fluconazole, 15 data points are outside the y-axis limits (max AUC0-24/MIC value was 3250.3); ICU intensive care unit; AUC0-24 area under the plasma concentration-time curve from zero to 24 h; fAUC0-24 free AUC0-24; MIC minimum inhibitory concentration; Cmin minimum observed plasma concentration; Cmax maximum observed plasma concentration
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter PK study for Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU)
J Roberts etc
TLDR: ++variable, need tailored approach w TDM
link.springer.com/article/10.1...
11.03.2025 12:44 β
π 18
π 4
π¬ 0
π 0
#IDOnc
05.03.2025 13:08 β
π 0
π 0
π¬ 0
π 0
#IDOnc
04.03.2025 17:38 β
π 0
π 0
π¬ 0
π 0
I donβt even have the words tbh. I truly hope this reaches people. #NurseSky #MedSky #IDSky
03.03.2025 01:24 β
π 10
π 4
π¬ 0
π 0
Definetly look at the OFID article
01.03.2025 17:03 β
π 1
π 0
π¬ 0
π 0
Prolonged abx*
01.03.2025 15:54 β
π 0
π 0
π¬ 1
π 0
Life threatening disease or is it just the mucosa barrier and does prolonged barrier help pts or harm them. Crp may be elevated for long time in these pts but abx will not change the underlying issue.
01.03.2025 15:33 β
π 2
π 0
π¬ 1
π 0
Yup I agree I only work with oncology patients and have had to educate our onc collegues on various tests and diagnosis. Lots of time it is lack of knowledge of how to interpret tests and when abx are appropriate. Strep mitis is one of the biggest examples of this. Does strep mitis cause severe
01.03.2025 15:33 β
π 1
π 0
π¬ 1
π 0
Decreasing Crp should not be used a marker to continue current broad abx if cultures and remain negative and no source seen. Decreasing crp can be from numerous reasons and not just giving abx. Onc ID stewardship def needed
01.03.2025 15:09 β
π 0
π 0
π¬ 1
π 0
It definitely can happen the question is do they develop bacteremia, pneumonia, is it viral or fungal. Difficult to say
I think you have room for a study.
01.03.2025 12:07 β
π 0
π 0
π¬ 1
π 0
I would make sure the CRP is not related to other factors such as relapse and starting emperic abx with CRP alone will increase your resistance eventually. This all can be helpful but also lead to more CRE and steno.
01.03.2025 11:40 β
π 1
π 0
π¬ 0
π 0